AngioDynamics (Nasdaq:ANGO) announced today that it received FDA investigational device exemption (IDE) to initiate the ...

OXFORD, UK / ACCESS Newswire / June 15, 2026 /Fine Treatment has highlighted increasing interest in non-invasive therapeutic ...

AngioDynamics ANGO recently announced that the FDA has approved its IDE application to initiate the RELIEF study, which will ...

The study will enrol up to 40 participants across a maximum of five clinical sites in the US.

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

The US Food and Drug Administration (FDA) has cleared Prodeon Medical’s implantable technology for treating lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). The ...

(NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today ...

The MarketWatch News Department was not involved in the creation of this content. SUNNYVALE, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Prodeon Medical, a privately held medical device company focused ...

A postmarketing study showed that the Optilume BPH system improved the flow of urine while leaving sexual function unchanged in men with benign prostatic hyperplasia (BPH), researchers reported at the ...

GREENBRAE, Calif.--(BUSINESS WIRE)--MarinHealth Medical Center (MHMC) announced today that its surgeons have performed the first Aquablation procedures to treat benign prostatic hyperplasia (BPH).

Benign prostatic hyperplasia (BPH) is the leading cause of lower urinary tract symptoms among the aging male population. Epidemiological, pathophysiological and clinical studies indicate that many of ...